25-07-2024 |
PM |
|
ABBV |
AbbVie Inc. |
305,760 |
2.65 |
2.56 |
2.91 |
AbbVie Non-GAAP EPS of $2.65 misses by $0.01, revenue of $14.46B beats by $430M [7/25/2024 7:37 AM] |
182.52 |
6.31 (3.58%) |
174.00 |
-2.21 (-1.25%) |
135.85 - 186.11 |
7,483,847 |
4,440,000 |
44,042 |
|
|
26-04-2024 |
PM |
|
ABBV |
AbbVie Inc. |
296,410 |
2.31 |
2.35 |
2.46 |
AbbVie Non-GAAP EPS of $2.31 beats by $0.05, revenue of $12.31B beats by $370M [4/26/2024 7:36 AM] |
159.54 |
-7.75 (-4.63%) |
166.49 |
-0.80 (-0.48%) |
130.96 - 182.89 |
8,943,996 |
5,140,000 |
54,821 |
|
|
02-02-2024 |
PM |
|
ABBV |
AbbVie Inc. |
290,250 |
2.79 |
2.76 |
3.60 |
AbbVie reports mixed Q4 results; raises FY24 outlook [2/2/2024 7:41 AM] |
168.64 |
1.05 (0.63%) |
168.96 |
1.37 (0.82%) |
130.96 - 172.85 |
6,230,525 |
5,020,000 |
76,139 |
|
|
27-10-2023 |
PM |
|
ABBV |
AbbVie Inc. |
258,240 |
2.95 |
2.85 |
3.66 |
AbbVie Non-GAAP EPS of $2.95 beats by $0.08, revenue of $13.93B beats by $220M [10/27/2023 7:39 AM] |
138.93 |
-6.27 (-4.32%) |
136.87 |
-8.33 (-5.74%) |
130.96 - 168.11 |
7,463,257 |
4,700,000 |
100,141 |
|
|
27-07-2023 |
PM |
|
ABBV |
AbbVie Inc. |
252,610 |
2.91 |
2.79 |
3.51 |
AbbVie Non-GAAP EPS of $2.91 beats by $0.10, revenue of $13.87B beats by $350M [7/27/2023 7:39 AM] |
148.85 |
6.95 (4.90%) |
144.00 |
2.10 (1.48%) |
130.96 - 168.11 |
10,828,942 |
5,130,000 |
309,718 |
|
|
27-04-2023 |
PM |
7:45 AM ET (Apr 27) |
ABBV |
AbbVie Inc. |
290,910 |
2.46 |
2.44 |
3.16 |
AbbVie Non-GAAP EPS of $2.46 misses by $0.03, revenue of $12.23B in-line [4/27/2023 7:34 AM] |
149.04 |
-12.76 (-7.89%) |
155.50 |
-6.30 (-3.89%) |
134.09 - 168.11 |
14,189,523 |
4,560,000 |
521,095 |
|
|
09-02-2023 |
PM |
7:45 AM ET (Feb 9) |
ABBV |
AbbVie Inc. |
256,680 |
3.60 |
3.54 |
3.31 |
AbbVie Non-GAAP EPS of $3.60 beats by $0.02, revenue of $15.12B misses by $180M, initiates FY outlook [2/9/2023 7:45 AM] |
148.70 |
4.09 (2.83%) |
147.77 |
3.16 (2.19%) |
134.09 - 175.91 |
10,197,853 |
5,300,000 |
307,866 |
|
|
28-10-2022 |
PM |
7:40 AM ET (Oct 28) |
ABBV |
AbbVie Inc. |
269,650 |
3.66 |
3.56 |
3.33 |
AbbVie Non-GAAP EPS of $3.66 beats by $0.10, revenue of $14.81B misses by $130M, raises dividend by 5% [10/28/2022 7:45 AM] |
147.50 |
-6.00 (-3.91%) |
146.00 |
-7.50 (-4.89%) |
108.20 - 175.91 |
9,191,067 |
4,740,000 |
174,215 |
|
|
29-07-2022 |
PM |
7:45 AM ET (Jul 29) |
ABBV |
AbbVie Inc. |
262,360 |
3.51 |
3.42 |
3.11 |
AbbVie Non-GAAP EPS of $3.37 beats by $0.06, revenue of $14.58B misses by $60M, cuts FY22 EPS guidance [7/29/2022 7:43 AM] |
143.65 |
-6.10 (-4.07%) |
146.70 |
-3.05 (-2.04%) |
105.56 - 175.91 |
15,064,137 |
5,030,000 |
31,351 |
|
|
29-04-2022 |
PM |
7:45 AM ET (Apr 29) |
ABBV |
AbbVie Inc. |
278,400 |
3.16 |
3.15 |
2.95 |
AbbVie Non-GAAP EPS of $3.16 beats by $0.02, revenue of $13.54B misses by $70M [4/29/2022 7:44 AM] |
146.85 |
-9.46 (-6.05%) |
148.93 |
-7.38 (-4.72%) |
105.56 - 175.91 |
20,338,728 |
7,630,000 |
209,424 |
|
-
All eyes on AbbVie Q1 results amid challenges to Humira's dominance [4/28/2022 12:13 PM]
-
Abbvie, Plexium team up to develop therapies for neurological disorders [4/28/2022 9:11 AM]
-
AbbVie Non-GAAP EPS of $3.16 beats by $0.02, revenue of $13.54B misses by $70M [4/29/2022 7:44 AM]
-
AbbVie down 8% after lowering full-year guidance, quarterly revenue miss (updated) [4/29/2022 8:42 AM]
-
AbbVie announces FDA approval of Rinvoq for new arthritic indication [4/29/2022 3:09 PM]
-
Dow Jones Futures Fall After Facebook-Led Market Rally; Apple Earnings Top, Amazon Tumbles [Apr-28-22 06:11PM]
-
Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN [Apr-28-22 10:53AM]
-
Why Earnings Season Could Be Great for AbbVie (ABBV) [Apr-28-22 09:35AM]
-
Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting [Apr-28-22 08:30AM]
-
Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions [Apr-28-22 08:00AM]
-
Eli Lilly (LLY) Q1 Earnings and Revenues Top Estimates [Apr-28-22 07:35AM]
-
AbbVie misses quarterly sales estimates as Humira rivals bite [Apr-29-22 07:48AM]
-
AbbVie Reports First-Quarter 2022 Financial Results [Apr-29-22 07:43AM]
-
AbbVie's stock is down 3% after missing on revenue in the first quarter of 2022 [Apr-29-22 08:07AM]
-
AbbVie Crumbles On Mixed Earnings, Slashes 2022 Profit Outlook [Apr-29-22 08:37AM]
-
AbbVie misses quarterly sales expectations on Humira competition [Apr-29-22 07:48AM]
-
AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs [Apr-29-22 10:02AM]
-
AbbVie misses sales estimates on Humira weakness, shares fall [Apr-29-22 07:48AM]
-
Stock Market Drops On Lackluster Earnings From Amazon, Apple [Apr-29-22 10:43AM]
-
AbbVie (ABBV) Tops Q1 Earnings Estimates [Apr-29-22 09:05AM]
-
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review [Apr-29-22 11:59AM]
-
AbbVie Plunges on Revenue Miss - Imbruvica and Humira Revenue Decline [Apr-29-22 06:10AM]
-
AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance [Apr-29-22 09:40AM]
-
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica [Apr-29-22 11:20AM]
-
Stock Market Down More Than 2%, Wiping Out Most Of Thursday's Rally; Amazon Hits Indexes [Apr-29-22 01:46PM]
-
RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis [Apr-29-22 02:44PM]
-
Why AbbVie's Shares Dropped 10.5% Friday [Apr-29-22 04:46PM]
-
10 Stocks Tumbling Today [Apr-29-22 03:54PM]
|
02-02-2022 |
PM |
7:40 AM ET (Feb 2) |
ABBV |
AbbVie Inc. |
243,830 |
3.31 |
3.28 |
2.92 |
AbbVie Non-GAAP EPS of $3.31 beats by $0.03, revenue of $14.89B misses by $70M [2/2/2022 7:45 AM] |
138.81 |
1.81 (1.32%) |
136.34 |
-0.66 (-0.48%) |
102.05 - 139.41 |
9,440,816 |
8,710,000 |
288,029 |
|
-
Gilead’s COVID-19 therapy beats AbbVie’s Humira to lead U.S. hospital spending in 2021 [2/1/2022 3:46 PM]
-
Will AbbVie's upbeat earnings pattern continue in Q4? [2/1/2022 7:38 AM]
-
AbbVie Non-GAAP EPS of $3.31 beats by $0.03, revenue of $14.89B misses by $70M [2/2/2022 7:45 AM]
-
AbbVie beats Q4 non-GAAP EPS forecast; 2022 guidance tops consensus [2/2/2022 8:32 AM]
-
Verity & Verity, LLC Buys LyondellBasell Industries NV, Verizon Communications Inc, ... [Feb-01-22 05:38PM]
-
Leonard Rickey Investment Advisors P.L.L.C. ... [Feb-01-22 01:38PM]
-
Is AbbVie Stock a Buy Now? [Feb-01-22 11:45AM]
-
Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO [Feb-01-22 09:45AM]
-
James Hambro & Partners Buys Netflix Inc, Pool Corp, Union Pacific Corp, Sells Comcast ... [Feb-01-22 09:38AM]
-
AbbVie Showcases Its Leadership in Research in Inflammatory Bowel Diseases with New Analyses to be Presented at the 17th Congress of European Crohn's and Colitis Organization (ECCO) [Feb-01-22 08:45AM]
-
Why AbbVie (ABBV) Might Surprise This Earnings Season [Feb-01-22 08:30AM]
-
3 Warren Buffett Dividend Stocks to Buy in February [Feb-01-22 05:56AM]
-
3 Pharmaceutical Stocks With Dividend Yields of 2.9% or Better [Feb-01-22 05:39AM]
-
AbbVie's Charts Look Strong Ahead of Earnings [Feb-01-22 05:22AM]
-
5 High-Yield Dividend Stocks That Can Save Your Portfolio During a Stock Market Crash [Feb-01-22 05:06AM]
-
Axel Capital Management, LLC Buys Silvergate Capital Corp, Riot Blockchain Inc, Meta Platforms ... [Feb-01-22 09:38PM]
-
Were Hedge Funds Right About AbbVie Inc (ABBV)? [Feb-02-22 01:17AM]
-
Greystone Financial Group, LLC Buys iShares U.S. ... [Feb-01-22 09:38PM]
-
AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results [Feb-02-22 07:43AM]
-
AbbVie's stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humana [Feb-02-22 08:06AM]
-
AbbVie's stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humira [Feb-02-22 08:21AM]
-
AbbVie Earnings Slightly Beat Estimates. Here Are the Numbers That Matter. [Feb-02-22 09:17AM]
-
AbbVie Earnings Come In Mixed, Though Guidance Offers A Hefty Beat [Feb-02-22 09:32AM]
-
Argent Advisors, Inc. Buys iShares 10-20 Year Treasury Bond ETF, Pinnacle West Capital Corp, ... [Feb-02-22 09:38AM]
-
Demars Financial Group, LLC Buys iShares TIPS Bond ETF, Medical Properties Trust Inc, Phillips ... [Feb-02-22 09:38AM]
-
Meridian Wealth Advisors, LLC Buys Vanguard S&P 500 ETF, Vanguard Mid-Cap ETF, JPMorgan ... [Feb-02-22 09:38AM]
-
AbbVie (ABBV) Tops Q4 Earnings Estimates [Feb-02-22 09:05AM]
-
AbbVie Sales Lag As Humira Competition Heats Up And U.S. Biosimilars Loom [Feb-02-22 12:13PM]
-
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss [Feb-02-22 11:40AM]
-
MV Capital Management, Inc. Buys Abbott Laboratories, AbbVie Inc, Fidelity Blue Chip Growth ... [Feb-02-22 01:38PM]
-
Truepoint, Inc. Buys Avantis Emerging Markets Equity ETF, Vanguard Intermediate-Term Corporate ... [Feb-02-22 01:38PM]
-
UPDATE 1-U.S. FDA approves first generic form of AbbVie's eye drug [Feb-02-22 01:52PM]
-
UPDATE 2-U.S. FDA approves first generic version of AbbVie's dry-eye drug [Feb-02-22 01:52PM]
-
Chase Investment Counsel Corp Buys Eagle Materials Inc, National Fuel Gas Co, AbbVie Inc, Sells ... [Feb-02-22 05:38PM]
|
29-10-2021 |
PM |
7:45 AM ET (Oct 29) |
ABBV |
AbbVie Inc. |
193,490 |
3.33 |
3.23 |
2.83 |
AbbVie EPS beats by $0.11, beats on revenue, raises guidance [10/29/2021 7:43 AM] |
114.53 |
4.86 (4.43%) |
111.96 |
2.29 (2.09%) |
79.11 - 121.53 |
13,233,217 |
5,310,000 |
241,915 |
|
-
AbbVie EPS beats by $0.11, beats on revenue, raises guidance [10/29/2021 7:43 AM]
-
AbbVie hikes dividend by ~9% to $1.41 per share, stock yields 5.2% [10/29/2021 7:47 AM]
-
AbbVie's cariprazine meets main goal in late-stage major depressive disorder study [10/29/2021 8:03 AM]
-
AbbVie sets better-than-expected 2021 guidance despite slowdown in topline growth [10/29/2021 8:17 AM]
-
FDA approves AbbVie's Vuity eye drops for age-related farsightedness [10/29/2021 1:53 PM]
-
What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report [Oct-28-21 12:46PM]
-
Should Investors Worry About AbbVie? [Oct-28-21 10:30AM]
-
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease [Oct-28-21 08:15AM]
-
AbbVie gets a shot in the arm from newer drug sales, lifts profit view [Oct-29-21 07:43AM]
-
AbbVie Reports Third-Quarter 2021 Financial Results [Oct-29-21 07:40AM]
-
AbbVie's Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder [Oct-29-21 07:50AM]
-
AbbVie Stock Rises on Earnings Beat and Guidance Boost [Oct-29-21 07:54AM]
-
UPDATE 1-AbbVie gets a shot in the arm from newer drug sales, lifts profit view [Oct-29-21 08:09AM]
-
Premarket Movers Friday - Amazon, AbbVie, Apple [Oct-29-21 04:49AM]
-
AbbVie Stock Nears Breakout After Topping Forecasts As Botox Sales Rocket [Oct-29-21 08:57AM]
-
AbbVie Stock Rises on Stronger-Than-Expected Q3, Lifted Guidance [Oct-29-21 05:57AM]
-
Drug maker AbbVie reports 'excellent' third quarter [Oct-29-21 10:28AM]
-
AbbVie (ABBV) Tops Q3 Earnings Estimates [Oct-29-21 09:05AM]
-
UPDATE 2-AbbVie confident of blockbuster drug replacements, lifts profit view third time [Oct-29-21 08:09AM]
-
AbbVie confident of blockbuster drug replacements, lifts profit view third time [Oct-29-21 07:43AM]
-
AbbVie Stock Gains After Hiking FY21 Earnings Outlook, Annual Dividend [Oct-29-21 08:04AM]
-
AbbVie Performs Third-Quarter Hat Trick Here's What You Need To Know [Oct-29-21 11:22AM]
-
Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab [Oct-29-21 10:41AM]
-
AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials [Oct-29-21 09:18AM]
-
AbbVie's (ABBV) Q3 Earnings Beat, 2021 EPS Guidance Raised [Oct-29-21 11:06AM]
-
5 Top Gainers for Friday: U.S. Steel, Lululemon, VeriSign [Oct-29-21 09:24AM]
-
AbbVie Stock Retakes Its 50-Day Line On Bullish Earnings Is It A Buy Right Now? [Oct-29-21 01:43PM]
-
Abbvie Jumps After Raising Dividend, Annual Profit Forecast [Oct-29-21 09:33AM]
-
Why Are CareDx Shares Slumping Despite Q3 Earnings Beat? [Oct-29-21 12:03PM]
-
AbbVie (ABBV) Q3 2021 Earnings Call Transcript [Oct-29-21 03:31PM]
-
U.S. Food and Drug Administration Approves VUITY (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision) [Oct-29-21 05:31PM]
-
Why AbbVie Shares Are Rising Today [Oct-29-21 12:44PM]
|
30-07-2021 |
PM |
7:40 AM ET (Jul 30) |
ABBV |
AbbVie Inc. |
209,390 |
3.11 |
3.11 |
2.34 |
AbbVie EPS beats by $0.08, beats on revenue, raises FY21 Non-GAAP guidance [7/30/2021 7:45 AM] |
116.24 |
-2.63 (-2.21%) |
119.00 |
0.13 (0.11%) |
79.11 - 119.15 |
7,001,281 |
5,180,000 |
37,987 |
|
-
AbbVie Q2 2021 Earnings Preview [7/29/2021 3:25 PM]
-
AbbVie EPS beats by $0.08, beats on revenue, raises FY21 Non-GAAP guidance [7/30/2021 7:45 AM]
-
AbbVie tops Q2 forecast; non-GAAP EPS outlook for FY21 raised [7/30/2021 8:15 AM]
-
AbbVie to advance beta-amyloid Alzheimer's candidate, abandons tau asset [7/30/2021 11:51 AM]
-
FTC drops antitrust complaint against AbbVie after Supreme Court declines case review [7/30/2021 2:35 PM]
-
Should You Buy AbbVie (ABBV) Ahead of Earnings? [Jul-29-21 11:09AM]
-
How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market [Jul-29-21 10:35AM]
-
Match Group (MTCH) to Post Q2 Earnings: Is a Beat in Store? [Jul-29-21 09:07AM]
-
Market Crash 2.0: Where to Invest $1,000 [Jul-29-21 08:31AM]
-
FDA Approves Expanded BOTOX® (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity [Jul-29-21 08:30AM]
-
Before AbbVie's Inc. (NYSE:ABBV) Earnings Call Tomorrow, Consider their Debt [Jul-29-21 02:22AM]
-
AbbVie raises annual profit forecast as Botox demand rebounds [Jul-30-21 07:49AM]
-
AbbVie raises annual profit forecast as Botox demand rebounds [Jul-30-21 07:46AM]
-
AbbVie Reports Second-Quarter 2021 Financial Results [Jul-30-21 07:44AM]
-
AbbVie Earnings Edge Past Views With Stock Right At Buy Point [Jul-30-21 07:58AM]
-
AbbVie cites growth of immunology business in the second quarter [Jul-30-21 08:17AM]
-
Amazon, Pinterest Fall Premarket; Chevron, P&G Rise [Jul-30-21 04:01AM]
-
UPDATE 1-AbbVie raises annual profit forecast as Botox demand rebounds [Jul-30-21 08:57AM]
-
AbbVie Boosts Full-Year Guidance as Sales Rebound From Pandemic [Jul-30-21 07:49AM]
-
AbbVie Boosts 2021 Guidance as Sales Rebound From Pandemic [Jul-30-21 09:35AM]
-
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical [Jul-30-21 08:50AM]
-
Have $500? Here Are 2 High-Yielding Healthcare Stocks to Consider [Jul-30-21 10:14AM]
-
AbbVie (ABBV) Q2 Earnings Match Estimates [Jul-30-21 09:05AM]
-
UPDATE 2-AbbVie expects Botox boom to power annual earnings [Jul-30-21 08:57AM]
-
AbbVie expects Botox boom to power annual earnings [Jul-30-21 07:49AM]
-
AbbVie Q2 Earnings Beats Consensus Slightly; Guides FY21 EPS Below Consensus [Jul-30-21 08:19AM]
-
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV [Jul-30-21 10:12AM]
-
AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised [Jul-30-21 11:40AM]
|
30-04-2021 |
PM |
7:40 AM ET (Apr 30) |
ABBV |
AbbVie Inc. |
196,670 |
2.95 |
2.77 |
2.42 |
AbbVie EPS beats by $0.12, beats on revenue [4/30/2021 7:43 AM] |
111.46 |
0.57 (0.51%) |
111.51 |
0.62 (0.56%) |
79.11 - 113.41 |
7,122,910 |
5,460,000 |
101,920 |
|
|
03-02-2021 |
PM |
7:45 AM ET (Feb 3) |
ABBV |
AbbVie Inc. |
180,610 |
2.92 |
2.85 |
2.21 |
AbbVie EPS beats by $0.07, beats on revenue [2/3/2021 7:39 AM] |
107.53 |
2.53 (3.92%) |
106.00 |
2.53 (2.45%) |
62.55 - 113.41 |
10,122,068 |
7,744,182 |
202,692 |
|
|
30-10-2020 |
PM |
7:45 AM ET (Oct 30) |
ABBV |
AbbVie Inc. |
148,850 |
2.83 |
2.75 |
2.33 |
AbbVie EPS beats by $0.06, beats on revenue [10/30/2020 7:49 AM] |
85.13 |
4.46 (5.53%) |
83.60 |
2.93 (3.63%) |
62.55 - 101.28 |
13,851,210 |
7,972,976 |
209,880 |
|
|
31-07-2020 |
PM |
7:45 AM ET (Jul 31) |
ABBV |
AbbVie Inc. |
170,970 |
2.34 |
2.24 |
2.26 |
AbbVie EPS beats by $0.14, beats on revenue [7/31/2020 7:46 AM] |
94.06 |
-1.98 (-2.06%) |
96.29 |
0.25 (0.26%) |
62.55 - 101.28 |
4,962,822 |
5,759,455 |
122,320 |
|
|